US FDA rule change could prompt rethink of pharma IP strategy
By Melissa Ritti ( July 29, 2026, 14:24 GMT | Comment) -- Employee mobility and growing collaboration have already elevated the strategic importance of trade secrets and process patents across the life sciences industry. A new US Food and Drug Administration proposal aimed at simplifying registration of distributed manufacturing networks could make those assets even more critical — and harder to protect.The US Food and Drug Administration is taking steps to modernize its regulation of distributed drug manufacturing, in a shift that could require heightened trade secret vigilance....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.